



Press Release

Lupin Makes an Acquisition in Germany

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
---------------------	-------------------	-------------------------	--------------------------

Mumbai, July 30, 2008: Lupin Limited announced today that it has acquired Hormosan Pharma GmbH (Hormosan), a German Sales and Marketing generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS).

Hormosan, with total sales of €6.8 Million for the year ended December 2007, develops, licenses and markets a range of generics in Germany. Hormosan has a complementary product portfolio with products in the Central Nervous System and Cardiovascular therapeutic segments.

Hormosan has created a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector. Besides strong key account management the company also has a successful in-house Regulatory team, Pharmacovigilance, Medical Information and Marketing teams.

Commenting on the acquisition, **Dr. Desh Bandhu Gupta, Chairman, Lupin**, said,

“This is in line with our M&A strategy to harness the potential of the leading global pharma markets. This move establishes a bridgehead in Germany and is our first acquisition in the important European market. Hormosan has strengths in the sales and marketing of its products nationwide, together with strong regulatory and pharmacovigilance capabilities that can strengthen our European knowhow. Lupin will be able to add significant value through its strengths in R&D and strong, complementary pipeline leading to major synergies and growth.”

About Lupin

Headquartered in Mumbai, Lupin Ltd. has successfully positioned itself as a transnational pharmaceutical Company with a wide global footprint. Over the years the Company has

moved up the value chain and has leveraged its strengths to build a formidable formulations business. The Company's business mix has improved with close to 70% of its revenues coming from formulations and 30% from APIs. Lupin is engaged in developing and marketing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The US is its largest market overseas and it continues to enjoy a strong position in the home market growing ahead of the industry in terms of its market share. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Currently positioned amongst the top five pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.

For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US\$ 694 million) and Rs.4,083 million (US\$ 102 million) respectively.

For further information please contact:

Lupin Limited:

Seema Ahuja

Head, Corporate Communications

Ph: +919920042046

022 66402323 Extn: 2531

Fax: 022 66402534

email:seemaahuja@lupinpharma.com

OR

Source PR

Archana Pradhan

Ph: +919820330505

email: archanapradhan@sourcepr.com

